Elekta’s MLCi2 multileaf collimator helps achieve a fine balance between the delivery of high doses to the target and reduced dose to healthy tissues outside of the target volume. MLCi2, which provides low integral dose even when using advanced delivery techniques, is driven by Elekta’s fully integrated digital control system.
Unlike non-digital systems, there is no lag in the transmission of information, ensuring continuous verification and accurate placement of all leaves. This allows faster, safer and more accurate delivery than non-digital systems.
The active leakage reduction mechanism in the Elekta MLCi2, uses diaphragms in both directions to automatically track the trailing leaf, thus reducing transmission. This feature plays a valuable role in reducing integral dose to the patient and therefore reducing the risk of induced secondary cancer.
With a comprehensive choice of delivery systems, Elekta is the ideal partner for ensuring that each clinic and patient receives the best system and treatment for their needs. Learn more about our solutions below and how they can expand your clinical practice.
At the forefront of clinical advancements, Elekta has been instrumental in delivering techniques like IGRT, IMRT, VMAT as well as SBRT and SRT. These techniques have given clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.